CHESTCOF COMBINATION PRODUCT COUGH LOZENGES

Indications

• General wellness support
• Anti-inflammatory effects
• Antioxidant activity
• Digestive aid
• Support for immune function

Dosage

Children: Paediatric dosing should be determined based on the specific extract and its intended use. Consultation with a healthcare provider is recommended for accurate dosing.

Adults: Dosage varies widely depending on the specific extract and formulation. It is essential to follow the manufacturer's instructions or consult a healthcare professional for appropriate dosing.

Mechanism of action

The mechanism of action of herbal extracts can vary significantly based on their constituents. Commonly, they exert their effects through multiple pathways including modulation of neurotransmitter systems, interference with inflammatory processes, or direct antioxidant activity. Some extracts may activate certain receptors or inhibit enzymes related to disease processes.

Pharmacodynamics

The pharmacodynamics of extracts is complex due to the presence of multiple active compounds which can have synergistic or antagonistic effects. These compounds may influence cellular signaling pathways, alter gene expression, or modulate immune response. The overall pharmacological profile is determined by the specific composition of the extract, its concentration, and the biological target it interacts with.

Pharmacokinetics

The pharmacokinetics of extracts involves absorption, distribution, metabolism, and excretion of the active compounds. Generally, herbal extracts are absorbed in the gastrointestinal tract, with bioavailability influenced by factors such as formulation, the presence of food, and individual metabolic differences. Compounds may undergo hepatic metabolism, and elimination can occur through urine or feces, depending on their chemical nature.

Pregnancy

Consult a healthcare professional before use, as the safety of the extract during pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use, as the safety of the extract during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Chronic bronchitis
• Peptic ulcers
• Gastroesophageal reflux disease (GERD)
• Chronic liver diseases
• Respiratory infections
• Adrenal insufficiency

Dosage

Adults: Refer to specific guidelines and clinical judgement. Dosage may vary based on the formulation and indication. Generally, a typical dose ranges from 5 to 15 grams of dried root per day, which can be adjusted according to individual response and clinical condition.

Mechanism of action

Glycyrrhizin, the major component of Glycyrrhiza, inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 2, which leads to increased cortisol levels and enhanced mineralocorticoid activity. This can result in sodium retention, potassium excretion, and increased blood pressure. Additionally, glycyrrhizin possesses anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines and may enhance the immune response against viral infections.

Pharmacodynamics

The pharmacodynamic effects of Glycyrrhiza are largely attributed to glycyrrhizin and its ability to modulate corticosteroid metabolism. Its anti-inflammatory properties contribute to the alleviation of symptoms in conditions like asthma and gastrointestinal disorders. The hepatoprotective effects are seen in its ability to reduce liver inflammation and fibrosis, which may be beneficial in chronic liver diseases.

Pharmacokinetics

Glycyrrhizin is well absorbed after oral administration, with peak plasma concentrations occurring within a few hours. It undergoes extensive metabolism in the liver, primarily through conjugation, leading to the formation of glucuronide metabolites. The half-life of glycyrrhizin can vary, but it is generally around 6 to 12 hours. The excretion of metabolites occurs mainly through the urine.

Contra-indications

• Hypersensitivity to glycyrrhiza or any of its components
• Severe renal impairment
• Hypertension
• Hypokalemia

Adverse effects

• Hypertension
• Hypokalemia
• Edema
• Headache
• Nausea
• Vomiting
• Muscle weakness
• Arrhythmias

Interactions

• May potentiate the effects of corticosteroids and other medications affecting blood pressure
• Concurrent use with diuretics may lead to hypokalemia
• May interfere with the metabolism of certain drugs metabolized by cytochrome P450 enzymes

Precautions

• Use with caution in patients with cardiovascular disease
• Monitor potassium levels in patients on long-term therapy
• Caution in patients with liver disease

Pregnancy

Glycyrrhiza should be used with caution during pregnancy. There is limited data on its safety, and high doses may lead to adverse effects such as hypertension.

Breast-feeding

Glycyrrhiza should be used with caution while breastfeeding, as its effects on lactation and neonates are not well established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Dried root powder
• Extracts (standardized and non-standardized)
• Tinctures
• Teas

Indications

• Insecticide for agricultural use
• Research tool in toxicology

Dosage

Children: Refer to the BNF for Children for specific dosing and administration guidelines.

Adults: Refer to the BNF for specific dosing and administration guidelines.

Mechanism of action

Methyl parathion acts primarily by inhibiting the enzyme acetylcholinesterase, which is essential for the breakdown of the neurotransmitter acetylcholine. Its active metabolite, methyl paraoxon, is a potent inhibitor of both acetylcholinesterase and butyrylcholinesterase. The inhibition of these enzymes results in the accumulation of acetylcholine at synapses, leading to overstimulation of cholinergic receptors and resultant toxic effects.

Pharmacodynamics

The pharmacodynamics of methyl parathion involve its action as a noncompetitive inhibitor of acetylcholinesterase, causing prolonged effects of acetylcholine due to its inability to be hydrolyzed. The resultant cholinergic toxicity can lead to symptoms such as muscle twitching, respiratory distress, and potentially fatal outcomes if not treated promptly. The extent of inhibition is dose-dependent, with significant toxicity occurring after substantial enzyme inhibition.

Pharmacokinetics

Methyl parathion is absorbed through the gastrointestinal tract and can also be absorbed through the skin and respiratory tract. It is metabolized in the liver to form methyl paraoxon, which is responsible for the majority of its toxic effects. The distribution of methyl parathion in body tissues is influenced by its lipophilicity, and it is primarily excreted as metabolites in the urine. The elimination half-life and specific pharmacokinetic parameters can vary based on individual metabolism and exposure levels.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution is advised when administering to nursing women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Liquid formulation

Indications

• Hyperlipidemia
• Cardiovascular disease prevention
• Inflammatory conditions
• Skin conditions (e.g., eczema)
• Digestive health
• Cognitive function support
• Stress and anxiety relief

Dosage

Children: Paediatric dosing is highly variable and should be determined based on age, weight

Adults: Dosage varies widely depending on the type of oil and its intended use. For dietary purposes, a common recommendation is 1-2 tablespoons of vegetable oil per day. For fish oil supplements, typical doses range from 1,000 to 3,000 mg of omega-3 fatty acids daily. Refer to specific product guidelines for accurate dosing.

Mechanism of action

Oils exert their effects primarily through the modulation of cellular functions and metabolic pathways. For example, omega-3 fatty acids found in fish oils are known to influence the production of eicosanoids, which are signaling molecules that regulate inflammation and immunity. Essential oils often act on the central nervous system and can influence neurotransmitter levels, contributing to their therapeutic effects.

Pharmacodynamics

Oils can impact various physiological processes, such as lipid metabolism, inflammatory response, and immune function. Essential fatty acids are integral to cellular membrane integrity and fluidity, influencing signal transduction pathways. The anti-inflammatory properties of certain oils can help reduce symptoms of chronic inflammatory conditions. Oils such as lavender and peppermint have been shown to have calming effects, possibly due to their interaction with neurotransmitter systems.

Pharmacokinetics

The absorption of oils occurs primarily in the gastrointestinal tract, where they are emulsified by bile salts. After absorption, fatty acids are transported via chylomicrons into the lymphatic system and subsequently enter the bloodstream. They are metabolized in the liver and can be stored in adipose tissue. The half-life of oils varies widely depending on the type and its constituents, with some components being rapidly metabolized while others have a prolonged presence in the body.

Pregnancy

Oils can be used during pregnancy, but it is important to consult a healthcare provider, as certain oils may not be safe in all situations.

Breast-feeding

Generally considered safe, but specific oils should be evaluated for potential effects on the infant.

Storage

Store in a cool, dry place away from direct sunlight, and ensure containers are tightly sealed to prevent oxidation.

Indications

• General anesthesia for surgical procedures
• Induction of anesthesia
• Maintenance of anesthesia during surgery
• Sedation in intensive care settings

Dosage

Children: Dosing for pediatric patients also depends on the specific volatile anesthetic used and the clinical scenario. It is crucial to refer to the BNF for Children for accurate pediatric dosing recommendations.

Adults: The dosage of volatile halogenated anesthetics varies based on the specific agent used and the clinical context. Typically, they are administered via vaporization with concentrations adjusted according to the patient's response and surgical requirements. Refer to specific anesthetic guidelines for detailed dosing.

Mechanism of action

Volatile anesthetics act primarily on the central nervous system by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) activity and inhibiting excitatory neurotransmission. They modulate various ion channels, including GABA_A receptors and two-pore domain potassium channels, leading to sedation, immobility, and amnesia.

Pharmacodynamics

The potency of volatile anesthetics is measured by the minimum alveolar concentration (MAC), which is the concentration required to prevent movement in response to surgical stimuli in 50% of patients. These agents produce dose-dependent effects on vital signs, causing cardiovascular and respiratory depression. They can also affect cerebral blood flow and intracranial pressure.

Pharmacokinetics

Volatile anesthetics have rapid pharmacokinetics due to their high lipid solubility, facilitating quick absorption and distribution in body tissues. They are primarily eliminated through exhalation, with minimal metabolism in the liver. Recovery from anesthesia occurs as the concentration of the anesthetic decreases in the body, allowing for rapid discharge from the anesthetic state.

Interactions

• rifampicin+volatilehalogenatedanaesthetics: Severe (increases risk of nephrotoxicity)
• volatilehalogenatedanaesthetics+amfetamines: Unknown (additive effect)
• methylphenidate+volatilehalogenatedanaesthetics: Unknown (increases risk of hypertension and arrhythmias)
• volatilehalogenatedanaesthetics+ephedrine: Unknown (additive effect)
• volatilehalogenatedanaesthetics+pseudoephedrine: Unknown (additive effect)
• volatilehalogenatedanaesthetics+xylometazoline: Unknown (additive effect)

Pregnancy

Use with caution; potential risks should be weighed against benefits.

Breast-feeding

Safety during breastfeeding has not been established; caution is advised.

Storage

Store in a cool, dry place, protected from light. Keep out of reach of children.

Mechanism of action

Acute poisoning ... is related to ... inhibiting action on enzyme acetylcholinesterase. Toxic manifestations generally occur only after more than 50% of plasma cholinesterase is inhibited. ... Methyl parathion ... depend on oxidative activation by replacement of thiono-sulfur with oxygen for ... toxicity. Methyl parathion has only a slight inhibitory action on acetylcholinesterase and butyrylcholinesterase, but its active metabolite, methyl paraoxon, is a potent inhibitor of both these enzymes. A study was conducted examining the inhibition of (Ca2+ and Mg2+)-ATPase by parathion (56382) and methyl parathion. Enzyme activity was assessed spectrophotometrically in pig erythrocyte membranes containing calcium2+ (Ca2+) and magnesium2+ and in solubilized membrane preparations incubated with the test agents. The enzyme response to ATP was biphasic. Equations expressing the kinetics of the substrate curves described two classes of the ATP binding active site, one with high affinity and low maximum rate and one with low affinity and high maximum rate. High affinity active sites were stimulated by low ATP concentrations (20 uM), whereas low affinity active sites were stimulated by high ATP levels (2 mM). Parathion and methylparathion dose dependently inhibited enzyme activity; parathion had a greater inhibitory effect than methylparathion. Lineweaver-Burke and Dixon plots indicated noncompetitive inhibition. Parathion and methylparathion induced enzyme inhibition occurred over a range of free calcium ion concentrations (0.5 to 5 mM); the inhibition was significantly greater at lower Ca2+ concentrations (1 to 100 uM) than at higher concentrations. The authors conclude that parathion and methylparathion inhibit ATPase activity by binding to a site on the enzyme rather than through an interaction with associated lipids. For more Mechanism of Action (Complete) data for METHYL PARATHION (6 total), please visit the HSDB record page.